The introduction of burosumab, the human monoclonal antibody directed against fibroblast growth factor 23 (FGF23) [2,3], marked a critical breakthrough in the treatment of inherited hypophosphatemic rickets (HR), a group of rare, genetically heterogeneous phosphate wasting disorders (prevalence of 3.9 per 100,000 live births) that impair bone mineralization and severely impact the quality of life of affected patients. Here, FGF23 is linked to hypophosphatemic rickets.